BiotechTube
Home/Incyte/Vijay Iyengar, M.D., Ph.D.
VI

Vijay Iyengar, M.D., Ph.D.

EVP, Head of Inflammation & Autoimmunity

Incyte

Therapeutic Areas

HematologyOncologyInflammation & Autoimmunity

Incyte Pipeline

DrugIndicationPhase
Jakafi (ruxolitinib)MyelofibrosisMarketed
Opzelura (ruxolitinib cream)Atopic DermatitisMarketed
Pemazyre (pemigatinib)CholangiocarcinomaMarketed
Zynyz (retifanlimab)Merkel Cell CarcinomaMarketed
Iclusig (ponatinib)CML, Ph+ ALLMarketed
Tabrecta (capmatinib)NSCLC (METex14)Marketed
Ruxolitinib + INCB106385Myelofibrosis (LIMBER)Phase 3
Ruxolitinib + INCB057643Myelofibrosis (LIMBER)Phase 2

Leadership Team at Incyte

HH
Hervé Hoppenot
Chief Executive Officer
SS
Steven Stein, M.D.
Chief Medical Officer
DD
Dashyant Dhanak, Ph.D.
Chief Scientific Officer
CS
Christiana Stamoulis
Chief Financial Officer
View full Incyte profile